Patents by Inventor Markus Hossbach

Markus Hossbach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS OF TREATING HUNTINGTON'S DISEASE
    Publication number: 20240131093
    Abstract: The present invention relates to adeno-associated viral (AAV) particles encoding siRNA molecules and methods for treating Huntington's Disease (HD).
    Type: Application
    Filed: July 12, 2023
    Publication date: April 25, 2024
    Inventors: Dinah Wen-Yee Sah, Fen Chen, Pengcheng Zhou, Xin Wang, Yanqun Shu, Jinzhao Hou, Jochen Deckert, Markus Hossbach
  • HNF4a saRNA compositions and methods of use
    Patent number: 11965163
    Abstract: The invention relates to saRNA targeting an HNF4a transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Grant
    Filed: September 28, 2021
    Date of Patent: April 23, 2024
    Assignee: MiNA Therapeutics Limited
    Inventors: Hans E. Huber, David Blakey, Jon Voutila, Monika Krampert, Markus Hossbach
  • Compositions and methods for treating Huntington's disease
    Patent number: 11951121
    Abstract: The present invention relates to small interfering RNA (siRNA) molecules against the HTT gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating Huntington's Disease (HD) using the siRNA molecules and AAV vectors.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: April 9, 2024
    Assignee: VOYAGER THERAPEUTICS, INC.
    Inventors: Dinah Wen-Yee Sah, Jinzhao Hou, Pengcheng Zhou, Xin Wang, Jochen Deckert, Markus Hossbach
  • Compositions and methods for inhibiting expression of RRM2 genes
    Patent number: 11920134
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a RRM2 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a RRM2 gene using said pharmaceutical composition; and methods for inhibiting the expression of RRM2 in a cell.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: March 5, 2024
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: John Frederick Boylan, Birgit Bramlage, Markus Hossbach, John Reidhaar-Olson
  • HNF4A SARNA COMPOSITIONS AND METHODS OF USE
    Publication number: 20240035026
    Abstract: The invention relates to saRNA targeting an HNF4a transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Application
    Filed: September 28, 2021
    Publication date: February 1, 2024
    Inventors: Hans E. Huber, David Blakey, Jon Voutila, Monika Krampert, Markus Hossbach
  • Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof
    Publication number: 20230365970
    Abstract: Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2?-O-methyl nucleotides and 2?-fluoro nucleotides. Further disclosed herein are siNA molecules comprising (a) a phosphorylation blocker, conjugated moiety, or 5?-stabilized end cap; and (b) a short interfering nucleic acid (siNA).
    Type: Application
    Filed: July 28, 2023
    Publication date: November 16, 2023
    Applicant: Aligos Therapeutics, Inc.
    Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
  • COMPOSITIONS AND METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS)
    Publication number: 20230332156
    Abstract: The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.
    Type: Application
    Filed: December 20, 2022
    Publication date: October 19, 2023
    Inventors: Dinah Wen-Yee SAH, Jinzhao HOU, Mathieu E. NONNENMACHER, Pengcheng ZHOU, Markus HOSSBACH, Jochen DECKERT
  • Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof
    Publication number: 20230332153
    Abstract: Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2?-O-methyl nucleotides and 2?-fluoro nucleotides. Further disclosed herein are siNA molecules comprising (a) a phosphorylation blocker, conjugated moiety, or 5?-stabilized end cap; and (b) a short interfering nucleic acid (siNA).
    Type: Application
    Filed: November 29, 2022
    Publication date: October 19, 2023
    Applicant: Aligos Therapeutics, Inc.
    Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
  • Compositions and methods of treating Huntington's disease
    Patent number: 11752181
    Abstract: The present invention relates to adeno-associated viral (AAV) particles encoding siRNA molecules and methods for treating Huntington's Disease (HD).
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: September 12, 2023
    Assignee: VOYAGER THERAPEUTICS, INC.
    Inventors: Dinah Wen-Yee Sah, Fen Chen, Pengcheng Zhou, Xin Wang, Yanqun Shu, Jinzhao Hou, Jochen Deckert, Markus Hossbach
  • MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF
    Publication number: 20230159929
    Abstract: Described are short interfering nucleic acid (siNA) molecules comprising modified nucleotides, compositions, and methods and uses thereof.
    Type: Application
    Filed: September 7, 2022
    Publication date: May 25, 2023
    Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
  • RNAS FOR COMPLEMENT INHIBITION
    Publication number: 20230095695
    Abstract: RNAs, such as miRNA and siRNA, and their use in treating complement-mediated disorders, are described.
    Type: Application
    Filed: February 13, 2021
    Publication date: March 30, 2023
    Inventors: Markus Hoßbach, Kathrin Hultsch
  • Modified short interfering nucleic acid (siNA) molecules and uses thereof
    Patent number: 11549110
    Abstract: Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2?-O-methyl nucleotides and 2?-fluoro nucleotides. Further disclosed herein are siNA molecules comprising (a) a phosphorylation blocker, conjugated moiety, or 5?-stabilized end cap; and (b) a short interfering nucleic acid (siNA).
    Type: Grant
    Filed: February 15, 2022
    Date of Patent: January 10, 2023
    Assignee: Aligos Therapeutics, Inc.
    Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
  • Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
    Patent number: 11542506
    Abstract: The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.
    Type: Grant
    Filed: January 6, 2021
    Date of Patent: January 3, 2023
    Assignee: Voyager Therapeutics, Inc.
    Inventors: Dinah Wen-Yee Sah, Jinzhao Hou, Mathieu E. Nonnenmacher, Pengcheng Zhou, Markus Hossbach, Jochen Deckert
  • Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof
    Publication number: 20220364096
    Abstract: Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2?-O-methyl nucleotides and 2?-fluoro nucleotides. Further disclosed herein are siNA molecules comprising (a) a phosphorylation blocker, conjugated moiety, or 5?-stabilized end cap; and (b) a short interfering nucleic acid (siNA).
    Type: Application
    Filed: March 5, 2021
    Publication date: November 17, 2022
    Applicant: Aligos Therapeutics, Inc.
    Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
  • Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof
    Publication number: 20220177888
    Abstract: Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2?-O-methyl nucleotides and 2?-fluoro nucleotides. Further disclosed herein are siNA molecules comprising (a) a phosphorylation blocker, conjugated moiety, or 5?-stabilized end cap; and (b) a short interfering nucleic acid (siNA).
    Type: Application
    Filed: February 15, 2022
    Publication date: June 9, 2022
    Applicant: Aligos Therapeutics, Inc.
    Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
  • ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING
    Publication number: 20220143071
    Abstract: The present invention relates to antisense-oligonucleotides having a length of at least 10 nucleotides, wherein at least two of the nucleotides are LNAs, their use as inhibitors of TGF-R signaling, pharmaceutical compositions containing such antisense-oligonucleotides and the use for prophylaxis and treatment of neurological, neurodegenerative, fibrotic and hyperproliferative diseases.
    Type: Application
    Filed: November 8, 2021
    Publication date: May 12, 2022
    Inventors: Markus HOSSBACH, Monika KRAMPERT, Hans-Lothar ARTH
  • HNF4A SARNA COMPOSITIONS AND METHODS OF USE
    Publication number: 20220090074
    Abstract: The invention relates to saRNA targeting an HNF4a transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Application
    Filed: September 28, 2021
    Publication date: March 24, 2022
    Inventors: Hans E. Huber, David Blakey, Jon Voutila, Monika Krampert, Markus Hossbach
  • Antisense-oligonucleotides as inhibitors of TGF-R signaling
    Patent number: 11213541
    Abstract: The present invention relates to antisense-oligonucleotides having a length of at least 10 nucleotides, wherein at least two of the nucleotides are LNAs, their use as inhibitors of TGF-R signaling, pharmaceutical compositions containing such antisense-oligonucleotides and the use for prophylaxis and treatment of neurological, neurodegenerative, fibrotic and hyperproliferative diseases.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: January 4, 2022
    Assignee: NEUROVISION PHARMA GMBH
    Inventors: Markus Hossbach, Monika Krampert, Hans-Lothar Arth
  • HNF4A saRNA compositions and methods of use
    Patent number: 11162099
    Abstract: The invention relates to saRNA targeting an HNF4a transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: November 2, 2021
    Assignee: MINA THERAPEUTICS LIMITED
    Inventors: Hans E. Huber, David Blakey, Jon Voutila, Monika Krampert, Markus Hossbach
  • C/EBP ALPHA SARNA COMPOSITIONS AND METHODS OF USE
    Publication number: 20210187007
    Abstract: The invention relates to saRNA targeting a C/EBP? transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Application
    Filed: December 9, 2020
    Publication date: June 24, 2021
    Inventors: Andreas Wagner, Robert Habib, Hans E. Huber, Pål Saetrom, Endre Bakken Stovner, Markus Hossbach, Monika Krampert, Hans-Peter Vornlocher